Celloid

Executive Summary

Celloid is a South Korean regenerative medicine company developing stem cell and engineered cell therapies for degenerative diseases and tissue repair. Founded in 2015, the company is currently in the preclinical stage, leveraging advanced cell culture and differentiation technologies to create its therapeutic candidates. While the field of cell therapy holds significant promise, Celloid faces typical early-stage risks including scientific validation, manufacturing scalability, and regulatory hurdles. The company operates in a competitive landscape with other stem cell developers, but its focus on specific degenerative indications may provide differentiation. Given its early stage, Celloid's near-term value hinges on achieving key preclinical milestones and securing funding to advance toward the clinic.

Upcoming Catalysts (preview)

• Q2 2026IND application for lead candidate40% success
• Q3 2026Presentation of preclinical efficacy data at a major conference70% success
• H2 2026Completion of Series A funding round50% success